PET measurement of hepatobiliary transport of Telmisartan in a therapeutic dose using [11C]Telmisartan in normal subjects as a determinant of nonlinear pharmacokinetics.
Phase 1
- Conditions
- Healthy male subjects
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. Renal artery stenosis, bilaterally or unilaterally after nephrectomy 2. Hyperkalemia 3. Liver or renal dysfunction 4. Cerebrovascular disorders 5. Hypotension 6. Severe bradycardia, or WPW or LGL syndrome by ECG 7. Medication or dietary supplement including St. John's wort within 7 days prior to PET study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Telmisartan hepatobiliary transport mechanism OATP1B1 SLCO1B1 nonlinear pharmacokinetics PET imaging healthy subjects
Comparing hepatobiliary transport pharmacokinetics Telmisartan other ARBs OATP1B1 SLCO1B1 healthy volunteers
Genetic polymorphisms SLCO1B1 ABCG2 impact Telmisartan hepatobiliary transport pharmacokinetics healthy individuals PET
Telmisartan drug interactions OATP1B1 SLCO1B1 inhibitors impact hepatobiliary transport clinical implications
PET imaging drug hepatobiliary transport pharmacokinetics [11C] tracers OATP1B1 SLCO1B1 probes healthy volunteers